drugset
drugset / Trial / NCT05337592

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

NCT05337592 ↗

Phase 1 Completed 72 enrolled Boehringer Ingelheim
RandomizedSequentialSingle-blindTreatment

Summary

Single-rising dose (SRD) part The main objectives of the SRD part of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1815368 in healthy male subjects following oral administration of single rising doses. Bioavailability (BA) part The main objective of the BA part is to investigate the relative bioavailability of a tablet formulation versus oral solution and to assess the influence of food on the relative bioavailability of the tablet formulation.

Timeline

Start
2022-06-14
Primary completion
2022-10-18
Completion
2022-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1815368 Unknown — Oral

Indications

No indication recorded.